DK3154957T3 - Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser - Google Patents
Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser Download PDFInfo
- Publication number
- DK3154957T3 DK3154957T3 DK15714185.4T DK15714185T DK3154957T3 DK 3154957 T3 DK3154957 T3 DK 3154957T3 DK 15714185 T DK15714185 T DK 15714185T DK 3154957 T3 DK3154957 T3 DK 3154957T3
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- histonmethyl
- honorable
- transfer
- transferases
- Prior art date
Links
- 102000016397 Methyltransferase Human genes 0.000 title 1
- 108060004795 Methyltransferase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382230 | 2014-06-16 | ||
| PCT/EP2015/056860 WO2015192981A1 (en) | 2014-06-16 | 2015-03-30 | Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3154957T3 true DK3154957T3 (da) | 2020-02-17 |
Family
ID=51136403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15714185.4T DK3154957T3 (da) | 2014-06-16 | 2015-03-30 | Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9840500B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3154957B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6527534B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106536509B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015276537B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2987978C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3154957T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2769648T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015192981A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3390383A1 (en) * | 2015-12-14 | 2018-10-24 | Fundacion para la Investigacion Medica Aplicada | 2,4,6,7-tetrasubstituted quinoline compounds as inhibitors of dna methyltransferases |
| AU2017250369A1 (en) * | 2016-04-15 | 2018-10-11 | Epizyme, Inc. | Amine-substituted aryl or heteroaryl compounds as EHMT1 and EHMT2 inhibitors |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US11278550B2 (en) | 2016-05-17 | 2022-03-22 | Duke University | Compositions and methods for the treatment of Prader-Willi syndrome |
| US11433068B2 (en) * | 2016-09-08 | 2022-09-06 | The General Hospital Corporation | Treatment of cancers having alterations within the SWI/SNF chromatin remodeling complex |
| US10829452B2 (en) | 2016-12-22 | 2020-11-10 | Global Blood Therapeutics, Inc. | Histone methyltransferase inhibitors |
| WO2018119065A1 (en) | 2016-12-22 | 2018-06-28 | Asddr, Llc | Use of histone methyltransferase inhibitors and histone deacetylase inhibitors for therapy of phelan-mcdermid syndrome |
| EP3600318A4 (en) * | 2017-03-31 | 2021-06-09 | Epizyme, Inc. | METHOD OF USING EHMT2 INHIBITORS |
| CN110621316B (zh) | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| US11111243B2 (en) | 2017-06-09 | 2021-09-07 | Global Blood Therapeutics, Inc. | Azaindole compounds as histone methyltransferase inhibitors |
| WO2018229139A1 (en) | 2017-06-14 | 2018-12-20 | Fundación Para La Investigación Médica Aplicada | Novel compounds for use in cancer |
| WO2019036384A1 (en) | 2017-08-15 | 2019-02-21 | Global Blood Therapeutics, Inc. | TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES |
| SG11202001090WA (en) | 2017-08-15 | 2020-03-30 | Global Blood Therapeutics Inc | Tricyclic compounds as histone methyl-transferase inhibitors |
| EA202090959A1 (ru) * | 2017-10-18 | 2020-07-13 | Эпизайм, Инк. | Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза |
| BR112020007585A2 (pt) * | 2017-10-18 | 2020-09-24 | Epizyme, Inc. | método para prevenir ou tratar um distúrbio sanguíneo, inibidor de ehmt2 e uso de um inibidor de ehmt2 |
| US12172991B2 (en) * | 2018-05-29 | 2024-12-24 | Council Of Scientific & Industrial Research | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof |
| WO2019243236A1 (en) | 2018-06-18 | 2019-12-26 | Fundación Para La Investigación Médica Aplicada | New anticancer drug combinations |
| CN112390791B (zh) * | 2019-08-14 | 2023-08-01 | 复旦大学 | 一类dna甲基转移酶1荧光探针及其用途 |
| AU2021320254A1 (en) * | 2020-08-07 | 2023-03-02 | Athos Therapeutics, Inc. | Small molecules for the treatment of autoimmune diseases and cancer |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CN115160294B (zh) * | 2022-06-27 | 2023-09-29 | 中山大学 | 一种G9a/GLP共价抑制剂及其制备方法及应用 |
| CN120965666A (zh) * | 2025-10-21 | 2025-11-18 | 四川大学华西医院 | 一种喹啉类化合物、制备方法和用途及其药物组合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221882B1 (en) * | 1997-07-03 | 2001-04-24 | University Of Iowa Research Foundation | Methods for inhibiting immunostimulatory DNA associated responses |
| AU6051800A (en) * | 1999-06-16 | 2001-01-02 | University Of Iowa Research Foundation, The | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
| DK1088818T3 (da) * | 1999-10-01 | 2005-03-14 | Hoffmann La Roche | Quinolin-4-yl-derivater |
| US6440995B1 (en) * | 1999-10-01 | 2002-08-27 | Hoffman-La Roche Inc. | Quinolin-4-yl derivatives |
| AU2002361846A1 (en) * | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| US20040192583A1 (en) | 2002-12-19 | 2004-09-30 | Satyanarayana Medicherla | Treatment of obesity and associated conditions with TGF-beta inhibitors |
| EP1633718B1 (en) * | 2003-06-17 | 2012-06-06 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s |
| CN101535295A (zh) * | 2006-10-12 | 2009-09-16 | 休普基因公司 | 用于调节dna甲基化的喹啉衍生物 |
| WO2008046085A2 (en) | 2006-10-12 | 2008-04-17 | Supergen, Inc. | Quinoline derivatives for modulating dna methylation |
| US7790746B2 (en) * | 2007-10-12 | 2010-09-07 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
| MX2011013666A (es) * | 2009-06-25 | 2012-03-06 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| JP5761816B2 (ja) * | 2009-08-12 | 2015-08-12 | 国立大学法人京都大学 | 多能性幹細胞から神経前駆細胞への分化誘導法 |
| EA201200653A1 (ru) * | 2009-11-07 | 2013-01-30 | Мерк Патент Гмбх | Гетариламинохинолины |
| EP2771012A4 (en) * | 2011-10-24 | 2015-06-24 | Glaxosmithkline Ip No 2 Ltd | NEW CONNECTIONS |
| AU2013237226A1 (en) * | 2012-03-19 | 2014-10-09 | Emory University | Quinazoline compounds and their use in therapy |
| EP2730558A1 (en) * | 2012-11-08 | 2014-05-14 | Ikerchem, S.L. | Indole derivatives, pharmaceutical compositions containing such indoles and their use as DNA methylation modulators |
| WO2014072391A1 (en) * | 2012-11-09 | 2014-05-15 | St-Ericsson Sa | Analog to digital conversion method with offset tracking and correction and analog to digital converter implementing the same |
| JP6338601B2 (ja) * | 2013-03-01 | 2018-06-06 | フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ | ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物 |
-
2015
- 2015-03-30 EP EP15714185.4A patent/EP3154957B1/en active Active
- 2015-03-30 WO PCT/EP2015/056860 patent/WO2015192981A1/en not_active Ceased
- 2015-03-30 US US15/315,326 patent/US9840500B2/en active Active
- 2015-03-30 CA CA2987978A patent/CA2987978C/en active Active
- 2015-03-30 AU AU2015276537A patent/AU2015276537B2/en active Active
- 2015-03-30 CN CN201580034131.4A patent/CN106536509B/zh active Active
- 2015-03-30 DK DK15714185.4T patent/DK3154957T3/da active
- 2015-03-30 JP JP2016573017A patent/JP6527534B2/ja active Active
- 2015-03-30 ES ES15714185T patent/ES2769648T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015276537A1 (en) | 2017-01-05 |
| US20170121316A1 (en) | 2017-05-04 |
| WO2015192981A1 (en) | 2015-12-23 |
| EP3154957B1 (en) | 2019-11-20 |
| JP6527534B2 (ja) | 2019-06-05 |
| CN106536509B (zh) | 2020-06-09 |
| CN106536509A (zh) | 2017-03-22 |
| CA2987978C (en) | 2022-08-16 |
| EP3154957A1 (en) | 2017-04-19 |
| ES2769648T3 (es) | 2020-06-26 |
| JP2017524668A (ja) | 2017-08-31 |
| AU2015276537B2 (en) | 2019-03-14 |
| US9840500B2 (en) | 2017-12-12 |
| CA2987978A1 (en) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3154957T3 (da) | Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser | |
| IL263586B (en) | Inhibitors of the menin-mll interaction | |
| DK3119772T3 (da) | Heteroaryl syk-hæmmere | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| IL248410A0 (en) | A system for the closed transfer of liquids | |
| DK3158054T3 (da) | Genetisk modificerede bakterier og fremgangsmåder til genetisk modifikation af bakterier | |
| DK3536685T3 (da) | Bicyklisk-fusionerede heteroaryl- eller arylforbindelser og anvendelse deraf som irak4 inhibitorer | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3207043T6 (da) | Dihydropyrrolopyridin-inhibitorer af ror-gamma | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| HRP20190407T1 (hr) | Heteroarilni spojevi za inhibiciju kinaza | |
| DK3718507T3 (da) | Anordninger til behandling af nedre ekstremitetsvaskulatur | |
| DK3227262T3 (da) | Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling | |
| DK3183260T3 (da) | Modificerede oligonukleotider og fremgangsmåder til deres syntese | |
| HRP20181899T1 (hr) | Biaril inhibitori kinaze | |
| DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3371165T3 (da) | Btk-inhibitor til anvendelse til behandling af kræft | |
| DK3313833T3 (da) | Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase | |
| DK3157929T3 (da) | Pyrazolforbindelser som modulatorer af fshr og anvendelser deraf | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| DK3481819T3 (da) | Forbindelser og anvendelse deraf til reducering af urisyreniveauer | |
| DK3215493T3 (da) | Syntese af copanlisib og dihydrochloridsalt deraf | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere |